Kindstar Global
Kindstar Global (Beijing) Technology, Inc. is a leading provider of specialty clinical testing services in China, offering a wide range of diagnostic and laboratory testing services to hospitals, including tertiary care facilities. Founded in 2003 and headquartered in Wuhan, the company focuses on esoteric diagnostic testing and has developed advanced medical testing technologies. Its services encompass various testing segments such as hematology, genetic diseases, infectious diseases, oncology, neurology, and maternal health, as well as COVID-19-related and routine testing. Kindstar Global also supports medical research and clinical trials, catering to the needs of physicians, pharmaceutical companies, and medical institutions. The company operates laboratories in major cities like Beijing, Shanghai, and Wuhan and maintains strategic alliances to enhance its service offerings while adhering to international standards and guidelines.
Haixi Biotechnology is a research and development company of medical testing reagents, aiming to provide accurate testing reagents for medical special inspections, and provide complete scientific research reagents and services for biomedical researchers. Haixi is committed to the R&D, production, sales and service of medical diagnostics and biomedical research reagent products.
NeoImmune is a technology developer focused on advancing the understanding and treatment of the immune system, particularly through the development of reagents for minimal residual disease (MRD) testing. The company specializes in high-throughput techniques for reading and writing T and B lymphocyte receptor profiles, which are essential for enhancing disease detection and clinical applications. Recently, NeoImmune completed a significant financing round to support the promotion of its MRD products and the research and development of new clinical innovations. The funding was led by Kangsheng Global, with participation from several notable investors, reaffirming NeoImmune's commitment to improving outcomes in hematological tumors and other diseases through cutting-edge immune system research.
TaiLai Biosciences is a biotechnology company based in Shanghai, China, specializing in multiomics technology for cancer research. The company focuses on developing non-invasive cancer screening and analysis tools that enhance researchers' understanding of cancer development and facilitate the creation of immune-guided therapies. TaiLai's innovative approach relies on proprietary biomultiomics technology, which integrates extensive biological data, including DNA, RNA, proteins, and metabolic small molecules. By employing bioinformatics and computational science, TaiLai aims to uncover correlations within this vast array of information. Additionally, the company offers a range of biopsy products and services tailored to advance cancer research and treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.